Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04718441
Other study ID # P00035263
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 10, 2021
Est. completion date July 30, 2024

Study information

Verified date May 2024
Source Boston Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This multicenter study aims to evaluate the accuracy of contrast-enhanced ultrasound (CEUS) in diagnosing abdominal solid organ injuries in pediatric patients. Up to 130 subjects will complete the study across approximately 5-10 sites in the US, with up to 30 patients in the training phase (3 per site) and 100 patients in the treatment phase of the study. All subjects will have had a CT scan as part of standard of care, confirming at least one solid organ abdominal injury. The study procedure will occur within 48 hours from time of injury. All subjects will have an abdominal ultrasound without contrast, followed by a contrast-enhanced ultrasound using the contrast agent Lumason. Ultrasound and contrast-enhanced ultrasound results will be compared to the CT scan results. The CT and ultrasound scans will be read locally and will undergo central review.


Description:

This is an interventional study which proposes to evaluate the accuracy of contrast-enhanced ultrasound (CEUS) in diagnosing abdominal solid organ injuries in pediatric trauma patients. Up to 130 subjects will be enrolled across approximately 5 to 10 sites in the US. Each site, including the coordinating center, will undergo the training phase; each site will enroll 3 participants in this phase successfully prior to entering the treatment phase. All subjects will have had a Computerized Tomography (CT) scan as part of standard of care, confirming at least one solid organ abdominal injury. All subjects will have an abdominal ultrasound without contrast, followed by a contrast-enhanced ultrasound using the contrast agent Lumason. Ultrasound and contrast-enhanced ultrasound results will be compared to the CT scan results. The study procedures will take place within 48 hours of injury. At conclusion of enrollment of all subjects a centralized review of CT vs. CEUS will occur to compare to real-time readings.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 68
Est. completion date July 30, 2024
Est. primary completion date May 9, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria: 1. Hemodynamically stable, as determined by the trauma team 2. Age 8 through 18 years (inclusive) 3. Interpretable CT of the abdomen and pelvis that demonstrates at least one solid organ injury among the liver, spleen, pancreas, and kidneys 4. Plan for observation or admission to the hospital 5. Candidate for abdominal ultrasound based on body habitus, as determined by the investigator 6. Glasgow Coma Score of 15 7. Able to complete the study procedures within 48 hours of injury Exclusion Criteria: 1. Known cardiac abnormality 2. Pulmonary Hypertension 3. Known sensitivity to any Lumason components - including sulfur hexafluoride, polyethylene glycol 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na), or palmitic acid 4. Unable to be rolled onto side to allow lateral ultrasound windows if necessary 5. Unable to assent or consent 6. Pregnant 7. Lactating 8. CT images not available for transmission to central image repository

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lumason
Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.

Locations

Country Name City State
United States Boston Children's Hospital Boston Massachusetts
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States University of Texas Southwestern Medical Center Dallas Texas
United States Phoenix Children's Hospital Phoenix Arizona
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
David Mooney

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall CEUS/CT Concordance for all study participants A patient is classified as having a "concordant" assessment if each organ identified by CT with injuries is exactly identified by CEUS, regardless of injury grade, by the local study site reviewer. Otherwise, a patient is classified as having a "discordant" assessment. At the time the CEUS is performed, within 48 hours of injury
Secondary Organ-specific CEUS/CT Concordance For each organ, a patient's organ is classified as having a "concordant" assessment if the presence or absence of an injury as identified by CT is exactly identified by CEUS. Otherwise, a patient is classified as having a "discordant" assessment. At the time the CEUS is performed, within 48 hours of injury
Secondary Grade-specific Overall CEUS/CT Concordance A patient is classified as having a "concordant" assessment if each organ identified by CT with injuries is exactly identified by CEUS, AND within 1 grade of the injury as identified by CT. Otherwise, a patient is classified as having a "discordant" assessment. At the time the CEUS is performed, within 48 hours of injury
Secondary Peritoneal Fluid CEUS/CT Concordance A patient is classified as having a "concordant" assessment if the absence or presence of peritoneal fluid identified by CT is also exactly identified by CEUS. Otherwise, a patient is classified as having a "discordant" assessment. At the time the CEUS is performed, within 48 hours of injury.
Secondary Real-time/Centralized CEUS Concordance A patient is classified as having a "concordant" assessment if the absence or presence of injury for each organ identified by 'real-time' CEUS with injuries is also exactly identified by centralized interpretation of CEUS images. At the time the CEUS is performed, within 48 hours of injury.
See also
  Status Clinical Trial Phase
Terminated NCT03147690 - Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children Phase 1/Phase 2
Completed NCT04865627 - Accuracy Activity Monitors for Inhospital Activity Monitoring of Geriatric Patients
Completed NCT03109483 - Effectiveness of the Geriatric Activation Program Pellenberg (GAPP) on the Geriatric Rehabilitation Ward N/A
Completed NCT04058015 - Outcome of Patients With Thoraco-abdominal Injury and Stress-induced Hyperglycemia or Diabetic Hyperglycemia
Completed NCT04978090 - Pilot Study Evaluating the Safety and Efficacy of a Patient-Specific Enteroatmospheric Fistula Isolation and Management Device Independent of Negative Pressure Wound Therapy N/A
Completed NCT03515811 - A Post Market Study to Confirm the Safety and Performance of the Signia™ Stapling System.
Recruiting NCT04937868 - Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
Completed NCT04282291 - Serratus Intercostal Plane Block,New Analgesia in Supraumbilical Surgery
Recruiting NCT05910567 - A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma N/A
Recruiting NCT03815370 - A Non-Traumatic Binder for Temporary Abdominal Wall Closure N/A